Early-life environmental factors can influence later-life susceptibility to cancer. Recent evidence suggests that metabolic pathways may mediate this type of latency effect. Previously, we reported that short-term exposure to dichloroacetic acid (DCA) increased liver cancer in mice 84 weeks after exposure was stopped. Here, we evaluated time course dynamics for key events related to this effect. This study followed a stop-exposure design in which 28-day-old male B6C3F1 mice were given the following treatments in drinking water for up to 93 weeks: deionized water (dH 2 O, control); 3.5 g/l DCA continuously; or 3.5 g/l DCA for 4-52 weeks followed by dH 2 O. Effects were evaluated at eight interim time points. A short-term biomarker study was used to evaluate DCA effects at 6, 15, and 30 days. Liver tumor incidence was higher in all DCA treatment groups, including carcinomas in 82% of mice previously treated with DCA for only 4 weeks. Direct effects of DCA in the short-term study included decreased liver cell proliferation and marked mRNA changes related to mitochondrial dysfunction and altered cell metabolism. However, all observed short-term effects of DCA were ultimately reversible, and prior DCA treatment did not affect liver cell proliferation, apoptosis, necrosis, or DNA sequence variants with age. Key intermediate events resulting from transient DCA exposure do not fit classical cytotoxic, mitogenic, or genotoxic modes of action for carcinogenesis, suggesting a distinct mechanism associated with early-life metabolic disruption.
, often beyond that seen with adult-only exposure, and that the scope of these latent effects extends well beyond direct mutagenic agents (Barton et al., 2005; Boekelheide et al., 2012; EPA, 2005a; Halmes et al., 2000) . This evidence has highlighted the need for biomarkers that are persistently altered following exposure to a potential carcinogen and clearly associated with risk later in life.
In 2005, the U.S. Environmental Protection Agency (EPA) issued a guidance addressing general issues and susceptibility factors related to early-life exposure to carcinogens (EPA, 2005a) . This document defined specific life-stage adjustments for carcinogenic potency, called age-dependent adjustment factors (ADAFs), but only for chemicals with a primary mutagenic mode of action (MOA). For carcinogens acting through a nonmutagenic MOA, or those in which the MOA is unknown, standard methods of quantitative risk assessment were recommended (ie, without ADAFs) (EPA, 2005b) . This distinction was based on a lack of sufficient information to determine general adjustments for nonmutagenic agents with latent carcinogenic effects. The guidance further noted that as new MOA information and methods for quantifying early-life risk estimates become available, ADAF recommendations would be updated to include pathways other than mutagenicity. The current case study was developed to support this effort and examine nongenetic effects that may persist and mediate health outcomes later in life.
The reference chemical for this study was dichloroacetic acid (dichloroacetate, DCA), which was widely studied in the 1990s as a disinfection by-product of drinking water chlorination (EPA, 2003) . Biochemically, DCA is similar to pyruvate and thus affects many fundamental pathways of cellular metabolism. Some of these effects may persist over time, which has led to the characterization of DCA as a metabolic reprogramming agent (Phan et al., 2014; Zhang and Yang, 2013) . Previously, we showed that early-life postnatal exposure to DCA for 10 weeks increased the incidence of liver cancer in male and female mice 84 weeks after exposure was stopped (Wood et al., 2015b) , capturing the majority of carcinogenic effect reported previously after !90 weeks of continuous exposure (DeAngelo et al., 1991) . However, there was no clear evidence of a persistent molecular footprint of DCA at 98 weeks of age. The primary goal of the current study was to investigate key drivers of this effect by mapping time course changes following early-life DCA exposure.
DCA disrupts cell metabolism through several different pathways. One of the most widely studied effects is inhibition of pyruvate dehydrogenase kinase (PDK). Decreased PDK activity facilitates oxidative metabolism by increasing pyruvate dehydrogenase (PDH) activity, reducing glycolysis, and shunting glucose into the mitochondria (Bonnet et al., 2007; EPA, 2003; Stacpoole et al., 2008; Zhang et al., 2016) . DCA can also irreversibly inhibit glutathione S-transferase zeta 1 (GSTZ1) (Tzeng et al., 2000) , an enzyme that helps protect cells against oxidative stress (Blackburn et al., 2006) . In the liver, DCA induces rapid accumulation of glycogen, resulting in cytoplasmic vacuolation and potential cell death of hepatocytes (DeAngelo et al., 1999; Kato-Weinstein et al., 1998) . Collectively, these effects may result in chronic oxidative stress, cytotoxicity, regenerative proliferation, secondary DNA damage, and cancer. For this study, we hypothesized that metabolic changes following DCA exposure would persist over time, leading to increased oxidative stress and cell injury with age.
MATERIALS AND METHODS
Study design. This experiment followed a stop-exposure design in which male B6C3F1 mice (n ¼ 404) were divided into the following treatment groups: deionized water (dH 2 O, control); 3.5 g/l DCA continuously; or 3.5 g/l DCA for 4, 10, 26, or 52 weeks followed by dH 2 O for up to 93 weeks. Groups are designated by DCA and dH 2 O treatment times separated by a vertical bar (eg, 10j83 indicates 10 weeks of DCA followed by dH 2 O for up to 83 weeks). Animals were humanely euthanized by CO 2 at study end for all groups and at eight interim time points (10, 15, 26, 31, 52, 57 , and 78 weeks of treatment) for a subset of groups ( Figure 1A ). Interim time points were selected to evaluate DCA carryover effects near-term (5 weeks) and longer term (!16 weeks). Liver samples were collected from all groups at all time points. A targeted short-term study was also conducted to investigate early dose-related effects of DCA on liver gene expression, cell proliferation, and apoptosis. For the latter study, male B6C3F1 mice (n ¼ 120) were randomized by weight to receive dH 2 O alone or with DCA added at 0.5, 1.0, 2.0, and 3.5 g/l (n ¼ 8 per group) for 6, 15, or 30 days ( Figure 1B ).
All animals were observed daily for clinical signs of toxicity and monitored regularly for water intake and body weight (BW Drinking water dosing. DCA (CAS 79-43-6, Aldrich, Milwaukee, Wisconsin) was administered in drinking water as previously reported (DeAngelo et al., 1999; Wood et al., 2015a) . Doses for chronic and short-term studies were selected based on prior carcinogenicity findings in male mice following long-term (DeAngelo et al., 1999) and transient (Wood et al., 2015a) exposures. The target 3.5 g/l dose in mice (429 mg/kg/day) was equivalent to 65 mg/kg/day in humans based on a scaling factor of BW 0.75 (EPA, 2003) . This dose is up to approximately 10 5 times greater than DCA concentrations measured in finished drinking water samples (33-160 lg/l) (EPA, 2003) and approximately 2.6 times greater than doses used clinically in studies of children and adolescents with congenital metabolic diseases (12.5 mg/kg every 12 h) (Stacpoole et al., 2008) . Actual DCA doses were estimated based on mean water intake, BW, and water DCA concentrations (DeAngelo et al., 1999) . Daily water consumption (ml/kg/day) by cage was measured every 4-5 weeks from weeks 4-89 in the chronic study and weekly in the short-term study. Water pH was adjusted to 6.8-7.2 using NaOH. Water solutions were stored at 4-6 C, changed every 5-7 days, and sampled and analyzed throughout both studies. Stock drinking water samples were prepared every 12-14 days and analyzed by ultraviolet absorption at 231 nm with a Beckman DU Series 600 spectrophotometer (Beckman Coulter, Brea, California) to confirm DCA concentration. Prior studies have shown DCA to be stable over a 1-to 2-week period (DeAngelo et al., 1996 (DeAngelo et al., , 1999 Herren-Freund et al., 1987) . Overall water consumption in the chronic study was 5-22% lower in DCA groups compared with controls (Supplementary  Table 1 ). This effect was more pronounced at earlier time points and quickly rebounded after DCA was stopped ( Supplementary  Figure 1) . By week 52, water intake was 100-125 ml/kg/day in all groups. In the short-term study, DCA showed a dose-related effect at 6, 15, and 30 days (33-39% lower intake at high dose) (Supplementary Table 2 ).
Liver histology and pathology. Necropsy procedures were conducted by pathology staff at CRL/Pathology Associates International (PAI; Research Triangle Park, North Carolina). Livers were grossly examined, weighed, fixed, trimmed, and processed into paraffin blocks. A portion of each liver (multiple lobes, mixed) was frozen for RNA and DNA analyses. Fixed tissues were placed in 10% buffered formalin and transferred to 70% ethanol after 18-24 h. In the chronic study, embedded tissues were sectioned at 5-6 lm onto glass slides and stained with hematoxylin and eosin (H&E) using standard procedures. Four sections of liver (two each from grossly normal portions of left and median lobes) were evaluated via light microscopy by a certified pathologist (GRO). Mass lesions were counted, collected, sectioned, and examined separately. Histopathologic examination of liver tissues used standard criteria and nomenclature for neoplastic and nonneoplastic lesions. Where applicable, lesion severity was scored using a qualitative 0-4 scale (0 ¼ absent,
Cell proliferation and apoptosis. Liver cell proliferation was determined by immunohistochemical (IHC) staining for proliferating cell nuclear antigen (PCNA) and 5-bromo-2 0 -deoxyuridine (BrdU). Apoptosis was evaluated by TdT-mediated dUTP nick end labeling (TUNEL). In the chronic study, labeling indices (LI)
were measured at all interim timepoints for PCNA and week 57 for TUNEL. In the short-term study, LIs were measured at 6, 15, and 30 days for BrdU and 30 days for TUNEL. IHC staining was performed at PAI using established methods (Eldridge and Goldsworthy, 1996 (Eldridge and Goldsworthy, 1996) . TUNEL staining was performed at Wood Hudson Cancer Research Laboratory (Newport, Kentucky) as described previously (Gavrieli et al., 1992; Snyder et al., 1995) using pretreatment of slides with protease K (Sigma Chemical Co) and staining with Tdt and biotinylated dUTP. Sections of mouse duodenum, epidermis, and postirradiation prostate were run as positive controls for BrdU, PCNA, and TUNEL staining, respectively. Nonimmune rabbit serum applied at the same concentrations as the primary antibodies served as a negative control for nonspecific BrdU or PCNA staining (none observed).
To quantify cell proliferation and apoptosis, slides were coded and cells in at least 10 randomly selected fields from the left liver lobe (excluding proliferative lesions) were visually counted (þ/À) via light microscopy at 40Â objective by an observer blinded to treatment groups. BrdU and PCNA staining was nuclear, whereas TUNEL staining was nuclear and/or cytoplasmic. A minimum of 2000 cells per section were counted and used to calculate a LI of %-positive cells. Minimum counts were based on previous estimates of background LIs in the B6C3F1 mouse liver (Eldridge et al., 1993; Snyder et al., 1995) . BrdU and PCNA staining was quantified at PAI, whereas TUNEL staining was quantified at Macro Micro Photoillustrations (Covington, Kentucky). Serum ALT. Blood was collected at necropsy and processed to serum. Serum alanine aminotransferase (ALT) was measured as an indicator of liver cytotoxicity with a Beckman DU Series 600 spectrophotometer using routine methods and standard kits (Sigma Chemical Co).
Nucleic acid isolation. For gene expression analysis, total liver RNA was isolated from frozen liver (approximately 20 mg per sample) homogenized in RNAzolRT (Molecular Research Center, Cincinnati, Ohio) with a Precellys 24 homogenizer (Bertin Technologies, Villeurbanne, France). DNA was removed via 4-bromoanisole phase separation followed by alcohol precipitation and wash. RNA was purified with the RNeasy MinElute column protocol (Qiagen GmbH, Hilden, Germany). RNA integrity was evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, California) and quantified using a Qubit fluorometer (ThermoFisher Scientific, Waltham, Massachusetts). DNA was isolated from frozen liver (approximately 25 mg per sample) following bead homogenization, as described for total RNA. Homogenates were centrifuged and then incubated for 1 h at 56 C with 40 ml of proteinase K (50 mg/ml stock) in a Vortemp mixer at low rpm. Lysates were purified using a QIAmp kit protocol (Qiagen GmbH) and precipitated with ethanol. DNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, Delaware).
RNA-sequencing.
A subset of 24 frozen liver samples from the short-term study were arbitrarily selected from the 0, 1.0, 2.0, and 3.5 g/l DCA groups at 6 days (n ¼ 6 per group) and used for whole-genome RNA-sequencing (RNA-seq). Sequencing was performed at Expression Analysis (EA; Q2 Solutions-Quintiles, Durham, North Carolina) as described previously (Hester et al., 2016) . cDNA libraries were generated from total RNA using the TruSeq Stranded Total RNA with RiboZero Gold Sample Prep Kit (Illumina, San Diego, California). Final libraries were analyzed using an Agilent 2100 Bioanalyzer (DNA 1000 kit), quantitated by reverse-transcription polymerase chain reaction (RT-qPCR) (KAPA Library Quant Kit, KAPA Biosystems), barcode-labeled, and sequenced on an Illumina HiSeq 2500 instrument with 2Â50 bp-paired end flow cells. Complete RNA-seq FASTQ datasets are available through the NCBI Gene Expression Omnibus (GEO) (www.ncbi.nlm.nih.gov/geo/) (accession no. GSE86065).
RNA-seq data were analyzed as described previously (Hester et al., 2016) . Basecall files were converted into FASTQ format (CASAVA v. 1.8.2) and demultiplexed. Adapters and low-quality bases (Q-score <7) on read ends were trimmed. Reads with any one base at !95% frequency, >4 Ns in a row, average quality score <25 or length < 25 nucleotides after trimming were removed using RNAv9 pipeline (EA, Q2 Solutions, Durham, North Carolina) (https://github.com/ExpressionAnalysis/ea-utils/; last accessed July 12, 2017). Quality-filtered reads were aligned to External RNA Controls Consortium (ERCC), Illumina and PhiX spike-ins, and off-target biological material sequences to evaluate library construction, sequencing, and potential DNA contamination. To quantify transcripts, clipped FASTQ files were aligned to the reference mouse genome (Mus musculus-GRCm38/ mm10) and transcriptome (RefSeq transcript 2015-02-02) in Partek Flow (Build v4.0.16.0128, St. Louis, Missouri). Gene counts were quantified using the Partek expectation maximization algorithm (Partek E/M) (Li and Dewey, 2011) and normalized to reads per kilobase of transcript per million mapped reads (RPKM) with a 0 count offset of 1. Results were then filtered to remove genes with maximum expression <1 across all samples. Differential gene expression analysis was performed on filtered, normalized RNA-seq counts with Partek Gene-Specific Analysis. This analysis uses transcript-specific data to identify the best response distribution (Normal, Lognormal with shrinkage, and Negative Binomial models) using (1) Akaike information criterion corrected for small sample size and (2) F-statistics and a false discovery rate (FDR) filter of 5% to identify significant differentially expressed genes (DEGs) between DCA treatment groups relative to control. Analyses of DEGs were conducted in Ingenuity Pathway Analysis (IPA) Knowledgebase (Qiagen) using tools for canonical pathway identification and upstream regulator analysis (http://pages.ingenuity.com/rs/ingenuity/images/0812%20up stream_regulator_analysis_whitepaper.pdf; last accessed July 12, 2017).
Target mRNA expression. Sequencing results from the short-term study were used to identify candidate genes that may be persistently altered in the long-term study. mRNA expression was measured using RT-qPCR in control and 3.5 g/l DCA groups at 6 days (acute); 10-week DCA stop-exposure groups at 10, 26, 52, 78, and 93 weeks (time course); control, 26-week, 52-week, and continuous DCA exposure groups at 78 weeks (long-term carryover); and continuous DCA exposure group at 93 weeks (age control). Nine target mRNAs were analyzed including metabolic genes highly induced in a dose-dependent manner at 6 days. Reference genes (Tbp, Rplp0, Rps18, and Ywhaz) were selected from a standard normalization panel based on RNA-seq data. Primers and probes were designed using the SYBR Green PrimePCR platform (Bio-Rad, Hercules, California), and cDNA was generated using iScript Reverse Transcription Supermix. RT-qPCR reactions were prepared using Bio-Rad SsoAdvanced Universal SYBR Green Supermix and run in duplicate on a BioRad CFX384 instrument. Differences in gene expression were quantified using the Pfaffl method (ratio ¼ (E target )
) (Pfaffl, 2001 ) and normalized by geometric averaging of multiple internal control genes for relative quantification (Vandesompele et al., 2002) .
DNA amplicon resequencing. DNA sequence variants were evaluated using the Illumina TruSeq amplicon platform for targeted resequencing (Wood et al., 2015a) . Liver DNA was analyzed from a total of 42 mice in the following groups from the chronic study: control (26, 78, and 93 weeks); 10-week DCA (10, 26, 52, 78, and 93 weeks); 26-week DCA (26 and 78 weeks); and 78-week DCA (78 weeks) (n ¼ 3-4 per group). Amplicons for target genes were adapted from the human TruSeq Amplicon Cancer Panel (n ¼ 38) or identified from the literature as having an association with liver cancer (n ¼ 27) (Wood et al., 2015a) . Mouse orthologs were generated using Illumina DesignStudio Software using the Mus musculus UCSC NCBI37/mm9 reference genome. Amplicons were designed within exonic or 3 0 /5 0 -UTRs using the Sanger Cosmic database (http://cancer.sanger.ac.uk/cancergenome/projects/cos mic/; last accessed July 12, 2017). Target regions were focused on sites of high mutational activity. Oligonucleotide DNA templates consisting of target and universal primer regions were generated, PCR-amplified using indexed primers, pooled, and sequenced on an Illumina MiSeq instrument. Acceptable amplicons corresponded to 472 target regions across 62 different genes. All samples were sequenced in duplicate using standard Illumina reagents and protocols. Amplicon data were generated in variant call format (.vcf) using Illumina MiSeq Reporter. Overall coverage was 104Â with an average of 131k clusters passing filter (PF) per sample. "Raw" variant calls (VCs) were identified based on differences with the mm9 reference sequence and quality-filtered using predefined Illumina exclusion criteria, including variant frequency (VF) <1%, genotype quality <30, IndelRepeatLength >8, low coverage (no genotype called), and high variant strand bias. A total of 11 326 VCs passed initial quality filters (n ¼ 5568 and n ¼ 5758 in "a" and "b" sample replicates, respectively). There was 92% concordance in total VCs PF and 79% overlap in exact VCs PF between replicates. Called variants were then examined in reference to parental strains for B6C3F1 hybrid mice. Briefly, mm9 coordinates for all VC loci (n ¼ 117) were converted to mm10 coordinates using the UCSC liftOver tool (https://genome.ucsc. edu/util.html; last accessed July 12, 2017) and screened for heterozygosity using the Sanger Institute reference genomes for C57BL/6NJ and C3H/HeJ strains (http://www.sanger.ac.uk/sci ence/data/mouse-genomes-project; last accessed July 12, 2017).
Other statistical analyses. In-life and histopathology data were analyzed using SAS statistical package v9.4 (SAS Institute, Cary, North Carolina) and Graphpad Software (http://graphpad.com/ quickcalcs/contingency1.cfm; last accessed July 12, 2017). Early mortality was evaluated using the LIFETEST procedure to generate Kaplan-Meier survival distributions, followed by pairwise testing of homogeneity between survival curves. A two-sided Fisher's Exact Test was used to evaluate group differences in liver lesion incidence and final variant number. Continuous data were screened for normality and homogeneity of variance. Analysis of variance (ANOVA) was used to determine group differences for continuous data meeting these criteria. For nonparametric data, group differences were evaluated using a Kruskal-Wallis ANOVA followed by Wilcoxon rank sum pairwise tests. For the shortterm study, a Jonckheere test was used to evaluate dose trends in LI data. Pairwise comparisons included treatment groups at each time point versus the respective control group. A Bonferroni multiple-comparison correction was applied to all related pairwise and trend test P values. Continuous data are reported as mean 6 standard error unless otherwise stated.
RESULTS
Early-Life DCA Exposure Did Not Increase Mortality Mortality incidence and survival curves in the chronic study are shown in Supplementary Table 1 and Supplementary Figure 2 , respectively. A Univariate Chi-Squares for the Log-Rank Test showed no significant association between overall mortality and liver tumor incidence. Similarly, pairwise testing of homogeneity between survival curves showed no significant differences between the dH 2 O control group and DCA treatment groups.
DCA Reduced Body Weight With Variable Recovery Times
Continuous DCA treatment in the chronic study resulted in progressively lower BW with increased duration of exposure compared with dH 2 O controls, from À5% at 10 weeks to À20% at 93 weeks ( Supplementary Figs. 3 and 4) . Upon withdrawal of DCA, BW recovered to control levels in all groups (prior to 93 weeks) (Supplementary Table 3 ). Recovery times for terminal BW varied from <5 weeks (52-week DCA) to >21 weeks (10-week DCA) ( Supplementary Figs. 3 and 4) .
Transient DCA Exposure Increased Cancer Incidence in All Treatment Groups Both incidence and number of hepatocellular (HC) carcinomas and combined HC adenomas/carcinomas were higher in all DCA treatment groups (P < .05 compared with dH 2 O controls) (Table 1  and Supplementary Table 4) . Continuous DCA treatment resulted in the highest incidence of HC carcinomas (93% at !52 weeks). Prior treatment with DCA for only 4 weeks captured most of this effect (82% incidence at !52 weeks). At 93 weeks of treatment, there were no statistically significant differences in the incidence of combined HC adenomas/carcinomas between any of the DCA treatment groups (P > .1 for all) (Supplementary Table 4 ). However, longer duration of DCA exposure did result in a greater number of HC tumors at !52 weeks (>2-fold higher tumors per animal in the 93-week DCA group compared with all other groups) (Table 1) and higher incidence of tumors at interim time points (Supplementary Table 4) . At the 57-and 78-week time points (combined), groups exposed to DCA for !52 weeks had significantly higher HC tumor incidence compared with the 10-and 26-week DCA exposure groups (P < .05 for all) (incidence ¼ 18%, 39%, 53%, 95%, and 100% for dH 2 O control, 10-, 26-, 52-, and 93-week DCA groups, respectively) (Figure 2A and Supplementary Table 4) .
DCA-Induced Transient Effects on Liver Weight, Hypertrophy, and Cytotoxicity
In the long-term study, continuous treatment with DCA increased relative liver weights at 10, 26, and 52 weeks (Supplementary Table 3 ). Increased weights persisted beyond 5 weeks but eventually returned to control levels in all stopexposure groups. For example, in the 10-week DCA exposure group liver weights returned to control levels by 31 weeks of treatment ( Figure 2B ). Weights then increased again later in the study, presumably due to expansion of proliferative lesions.
The most prominent nonneoplastic effect of direct DCA exposure was moderate to severe HC hypertrophy (cytomegaly), observed at all time points in the long-term study (Supplementary Table 6 and Figure 2C ). This change was associated with marked cytoplasmic vacuolization; minimal to mild pigmentation, likely due to cholestasis secondary to the marked HC hypertrophy; and minimal to mild HC necrosis (Supplementary Table 6 and Figure  2C ). DCA effects on HC hypertrophy generally tracked liver weight and resolved sometime after 5 weeks of recovery ( Figure  2D ), whereas HC necrosis resolved within 5 weeks of discontinuing DCA treatment in all stop-treatment groups ( Figure 2E ). All of these morphologic effects had resolved by 31 weeks for the 10-week DCA group, by 57 weeks for the 26-week DCA group, and by 78 weeks for the 52-week DCA group.
DCA Increased Foci but Decreased Short-Term Liver Cell Proliferation
The overall incidence of proliferative HC foci was higher in DCA stop-exposure groups (13-27%) compared with controls (5%) at !31 weeks (Supplementary Table 7 ). The 26-week (basophilic foci only) and 52-week (all foci and basophilic foci) DCA exposure groups had statistically significant increases compared with controls ( Figure 3A) . However, this effect was not associated with sustained induction of cell proliferation in the liver. The PCNA LI was generally low (<1.0%) across all treatment groups compared with proliferative lesions (foci and tumors), which had a mean LI of 5.9 6 0.8%. Direct DCA treatment resulted in significantly higher PCNA LI at 10 weeks (0.3% vs 0.1% in controls, P < .05) but not at other interim time points (Supplementary Table 8 and Figure 3B ). Prior DCA treatment did not result in significantly greater PCNA LI in any group at any time point ( Figure 3B) , and direct or prior DCA exposure did not significantly alter TUNEL LI at 57 weeks (Supplementary Table 8 ).
In the short-term dose-range study, direct DCA treatment increased absolute and relative liver weight in a dose-dependent manner starting at 6 days (Supplementary Table 5 and Figure 3C ) but did not induce a corresponding mitogenic effect. Rather, cell proliferation determined by BrdU LI was significantly lower in the 2.0 and 3.5 g/l DCA groups at 6 and 15 days (Supplementary Table 9 ; Figs. 3C and D) . No significant group differences were observed for TUNEL LI at 30 days (Supplementary Table 9 ).
DCA-Induced Marked Disruption of Metabolic Pathways
Acute transcriptomic changes were measured by RNA-seq after 6 days of DCA treatment. Sequencing quality metrics are available in Supplementary Table 10 . DCA treatment resulted in 943, 5602, and 5678 DEGs in the 1.0, 2.0, and 3.5 g/l dose groups, respectively, and clear separation of dose groups on PCA ( Figure 4A ). General concordance in DEGs and target pathways was seen across DCA doses; for example, the 3.5 g/l dose captured 84% (738/943) and 73% (4079/5602) of DEGS in the 1.0 and 2.0 g/l dose groups, respectively ( Figure 4B ). Highly altered DEGs related to fatty acid degradation/metabolism, including known targets of peroxisome proliferator-activated receptor (PPAR) signaling (eg, Cyp4a and Acot series, Ehhadh, Scd1) (up), protease inhibition (eg, Serpina1e, Mug1, Itih1) (down), long-chain fatty acid synthesis (Elovl3) (down), and gluconeogenesis (Ppargc1a, Ppard and Pck1) (down). A full list of RPKM-normalized DEG counts is provided in Supplementary Table 11 . The most highly ranked canonical pathways at the 3.5 g/l DCA dose were Mitochondrial Dysfunction, Oxidative Phosphorylation, and NRF2-mediated Oxidative Stress Response ( Figure 4C and Supplementary Table  12 ). Highly represented gene families included mitochondrial complex NADH:ubiquinone oxidoreductase subunits (NDUFs), cytochrome c oxidases, heat shock proteins, and ATP synthases (Supplementary Table 13 ). Further analysis of upstream transcriptional regulators for DEGs identified PPARa and rapamycininsensitive companion of mTOR (RICTOR) as the top-ranked activated and inhibited regulators, respectively, at both the 2.0 and 3.5 g/l doses of DCA (Supplementary Table 14) . Collectively, these changes indicated marked dysregulation of oxidative metabolism in the mitochondria and altered lipid and glucose homeostasis centered on acetyl coenzyme A (Ac-CoA). We next examined the persistence of select target genes over time in liver samples from the chronic stop-exposure study. mRNAs related to metabolic disruption that were strongly induced by acute exposure to DCA (eg, Cyp4a10 and Cyp4a14) all returned to control levels within 5 weeks of stopping DCA ( Figs. 4D and E; Supplementary Table 15 ). Two genes repressed by DCA, Herpud1 and Serpina1e, remained lower after DCA exposure but were also lower in dH 2 O control groups at 78 and 93 weeks, suggesting that the lower expression was due to age rather than prior DCA treatment.
DCA Did Not Increase DNA Sequence Variants
Sequence variants in liver DNA were evaluated in 1348 target loci across 62 key cancer-related genes using targeted resequencing.
The goal was to evaluate time course effects of prior DCA treatment on DNA sequence variants. We predicted that variants would increase with age and that DCA treatment would amplify this effect. Quality-filtered variants at >1% frequency were initially identified at 160 loci ( Figure 5A and Supplementary  Table 16 ). Average frequency for initial VCs PF was consistent between replicates and across individual samples (47% overall) ( Figure 5B ). Heterozygosity between parental strains (corresponding to reference and variant bases) was identified for 84% (134/ 160) of variant loci covering 95% (4140/4354) of all filtered VCs ( Figure 5C and Supplementary Table 16 ). All of these heterozygosity VCs were located at the exact base coordinate(s) except for one (GSTA1), which was identified at a locus 2 bases from the target site (likely coordinate error). In addition, 4% (191/4354) of filtered VCs were located at insertion, deletion, or start/end sites of nucleotide repeat sequences (eg, G > GA base variant called at break site of G > 7 A bases) and potentially a result of technical PCR error (Clarke et al., 2001) . The remaining 23 VCs were considered actual base changes. Among these VCs, there were no apparent age-related effects and no effects of direct or prior DCA exposure ( Figure 5D ).
DISCUSSION
Metabolic trajectories established early in life can affect health outcomes later in life, including cancer. Environmental determinants of these metabolic shifts are poorly understood. DCA is a structural analog of pyruvate with distinctive effects on cellular metabolism and bioenergetics. Previously we demonstrated Supplementary Table 7 . Note that the higher cumulative incidence in the 4-week DCA treatment group may be influenced by the lack of interim time points. B, Cell proliferation labeling index (LI) (%-positive cells) for current and prior DCA treatment in morphologically normal liver. C, Short-term dose effects of direct DCA exposure on liver cell proliferation LI determined by BrdU labeling index (%-positive cells). D, Representative images of BrdU labeling in liver sections from normal control and 3.5 g/l DCA groups at 6 days. Background staining with hematoxylin, 20Â objective magnification. Full cell proliferation LI data sets are provided in Supplementary Tables 8 and 9 . *adjusted P < .05 compared with dH 2 O Con group;ˆadjusted P < .05 for dose trend. latent effects of DCA on liver carcinogenesis in mice (Wood et al., 2015a) . Here we investigated time course patterns for key events driving this effect. Early adult exposure to DCA for only 4 weeks resulted in 82% incidence of liver carcinoma at 97 weeks of age, capturing 86% of the carcinogenic effect observed with continuous DCA exposure at the same dose. Shortterm genomic profiles showed marked disruption of lipid and carbohydrate metabolism pathways centered on Ac-CoA, including mitochondrial dysfunction, oxidative phosphorylation, and oxidative stress response. No evidence of direct mitogenesis, mutagenesis, or persistent cytotoxicity was observed.
Collectively, these findings demonstrate long-term carcinogenic effects associated with transient metabolic disruption early in life.
The direct effects of DCA persisted for varying lengths of time after stoppage of treatment. The most pronounced morphologic changes were increased liver weight, hepatocellular hypertrophy, and cytoplasmic vacuolation, which lasted up to 26 weeks after stopping DCA treatment. These effects have previously been attributed to glycogenosis (EPA, 2003; KatoWeinstein et al., 1998; Lingohr et al., 2002; Sanchez and Bull, 1990) , which may be part of a misguided "energy overload" response induced by the pyruvate-like structure of DCA. Interestingly, the short-term mRNA profiles observed here did not highlight pathways specifically related to glycogen metabolism, and it is unclear to what extent these morphologic changes reflected transcriptional effects of DCA. Other effects included minimal to mild hepatocellular necrosis, inflammation, and pigmentation, all of which resolved within 5 weeks of stopping DCA in all stop-treatment groups, indicating a lack of sustained (or recurrent) cytotoxicity. All morphological outcomes were thus washed out in each DCA stop-treatment group prior to onset of tumors, raising the question of what molecular changes may have persisted and driven this later effect.
Our first rule-out was increased cell proliferation, which is a central key event in most established nongenotoxic MOAs for chemical carcinogens (Holsapple et al., 2006; Wood et al., 2015b) . Primary causes of increased cell proliferation are mitogenesis and sustained cytotoxicity. Here, we found that short-term DCA exposure decreased cell proliferation in a dose-dependent manner under exposure conditions of previous chronic studies. This acute antiproliferative effect is distinctive among known (nonmutagenic) chemical carcinogens. Longer term direct exposure (!10 weeks) resulted in modest increases in cell proliferation, likely in response to the mild hepatocellular necrosis. The impact of this regenerative effect on latent carcinogenicity, if any, is considered minor given that it was not consistent across DCA treatment groups (statistically significant only at 10 weeks) and did not persist. This response may have contributed to the higher tumor number and earlier tumor onset in groups Supplementary Table 15. exposed to DCA for longer durations (!52 weeks), but it was not required for the latent carcinogenic effect to occur given that the clear carcinogenic effect seen after 4 weeks of DCA treatment in the chronic study did not correspond to increased cell proliferation at 6, 15, or 30 days in the short-term study. Thus, for the 4-week DCA group, there was no evidence of a proliferative effect at any point during the exposure window (based on short-term study) or after the exposure window (based on longterm study). Collectively, these findings strongly suggest that classical mitogenic or cytotoxic proliferation-mediated pathways are not primary drivers for the latent carcinogenicity of DCA.
Another rule-out was direct DNA damage or mutagenicity, which has been investigated previously as a potential MOA for DCA-induced carcinogenesis following chronic exposure (DeAngelo et al., 1991 (DeAngelo et al., , 1996 Leavitt et al., 1997) . Several health authorities have concluded that DCA is acting primarily through nongenotoxic mechanisms, although a definitive MOA has not been established (EPA, 2003; IARC, 2004; WHO, 2000) , and select studies have reported evidence of mutagenic potential. For example, one experiment in male transgenic B6C3F1 mice harboring the bacterial lacI gene found a significant increase in mutant frequency in the liver after 60 weeks of DCA treatment at 3.5 g/l (but not after 4 or 10 weeks of treatment) (Leavitt et al., 1997) . Here, we used amplicon resequencing to survey sites of high mutational activity across 62 oncogenes and tumor suppressor genes and found no effects of direct or prior DCA exposure.
The consistent detection of strain-dependent heterozygous variants (at approximately 50% frequency) supports the accuracy of this platform. However, the low number of total variants and lack of time course effects suggest that the 1% VF threshold for the assay is simply too high for reliable detection of age-related variants. These findings are also consistent with data from the previous stop-exposure study, which showed no effect of prior DCA on DNA variants at 98 weeks of age (Wood et al., 2015a) .
The transcriptional effects of DCA were generally consistent with increased pyruvate load, PDH activity, and oxidative mitochondrial metabolism. Recent studies suggest that this metabolic shift may decrease cell proliferation in various cancer cell lines treated with DCA (De Preter et al., 2016) . Our data indicate that acute antiproliferative effects may also occur in normal liver cells in vivo (ie, in the absence of an aerobic glycolytic phenotype). However, direct links between the metabolic and later carcinogenic effects are not clear at this point. Overall genomic responses to DCA at 6 days were overwhelming (>5500 DEGs for 3.5 g/l dose), which may have obscured primary targets. Growth factor signaling pathways such as insulin or signal transducers and activators of transcription 5 (STAT5) were not represented in top-ranked pathways, and we did not see clear targeted effects on genes related to GSTZ activity or apoptosis/cell survival. We did note strong induction by DCA of many known PPARa targets, many of which were increased by >100-fold. Further work is needed to determine whether this pattern represents an actual PPARa-dependent effect, given that previous studies of DCA report inconsistent or weak induction of peroxisomal enzyme activity (Corton, 2008) and no short-term mitogenic effects (typical of PPARa-activating liver carcinogens) were observed, or simply a convergent pattern due to an overall increase in peroxisomal oxidation of fatty acids secondary to increased Ac-CoA.
Paradoxically, much of the recent interest in DCA has focused on its role as a cancer preventive agent, based primarily on its ability to decrease conversion of glucose to lactate. This metabolic shunt, which is mediated by inhibition of PDK and activation of PDH, effectively blocks the preferred route of glucose Supplementary Table 16. metabolism for many types of cancer cells, known as the Warburg effect (Gatenby and Gillies, 2004; Sutendra and Michelakis, 2013; Vander Heiden et al., 2009) . DCA has thus been used experimentally as an "anti-Warburg" agent that increases mitochondrial oxidative phosphorylation at the expense of lactate production. Glycolysis-derived pyruvate can also be used to generate cytosolic Ac-CoA (Shyh-Chang and Daley, 2015) , which was a key node for many of the genomic targets altered by DCA at 6 days. A recent study (Moussaieff et al., 2015) showed that DCA, by redirecting pyruvate toward Ac-CoA, increased histone acetylation and increased pluripotency in embryonic stem cells. Although there are important differences in reprogramming of somatic and embryonic cells, these findings point to potential interactions between Ac-CoA resulting from DCA and epigenetic regulation of cell differentiation.
In 2011, Hanahan and Weinberg (2011) highlighted dysregulation of energy metabolism as an emerging hallmark of cancer, based on the idea that neoplastic cells require fundamental changes in cellular bioenergetics to support their increased growth and energy demands. In this study, we examined the long-term carry-over effects of a classical metabolic disrupting chemical. Transient exposure to DCA for a relatively short duration resulted in clear carcinogenic effects approaching that seen with lifetime exposure. This latent effect was associated with dramatic acute changes in oxidative metabolism but not shortterm mitogenesis, sustained cytotoxicity, or increased DNA variants. Key intermediate events thus did not fit the classical modes of action for chemical carcinogenesis. Additional studies are needed to examine whether early-life metabolic disruption by DCA alters oxidative DNA damage, bioenergetic profiles, and epigenetic changes such as DNA methylation later in life. More broadly, this work should inform efforts to identify predictive biomarkers and model chemical effects based on short-term exposures.
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